AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-11. (Cancelled)

12. (Currently amended) A compound of formula (I):



(I)

wherein:

Ar is phenyl which can be optionally substituted by one or more groups selected from halogen, hydroxy, cyano, C_1-C_8 alkyl (itself optionally substituted by one or more hydroxy or cyano groups or fluorine atoms), CH_2-R^2, $CH_2O(CH_2)_nOC_{1-6}$ alkyl, C_1-C_8 alkyl-NR^3-R^4;

R^2 is a 5 to 7-membered saturated ring containing 1 or 2 heteroatoms selected from nitrogen, oxygen and sulphur, an aryl or 5- to 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from nitrogen oxygen and sulphur, each of which can optionally substituted by one or more substituents selected from hydroxyl or hydroxymethyl;

R^3 is hydrogen or C_{1-6} alkyl and R^4 is C_{1-6} alkyl optionally substituted by one or more groups selected from hydroxyl or phenyl,

n is 1 to 4;

R^1 is hydrogen or phenyl optionally substituted by halogen, C_1-C_8 alkoxy, C_1-C_8 thioalkyl or C_1-C_8 alkyl;

~~and~~or a pharmaceutically acceptable salt thereof.

13. (Previously presented) A compound according to claim 12 in which R^1 is hydrogen.

14. (Previously presented) A compound according to claim 12 in which Ar is a phenyl optionally substituted by one or more CH_2R^2 groups, where R^2 is pyrrolidine, morpholine or imidazole each of which is optionally substituted as defined in claim 12.

15. (Previously presented) A compound according to claim 12 in which Ar is a phenyl optionally substituted by one or more CH_2R^2 groups where R^2 is pyrrolidine, morpholine or imidazole each of which is optionally substituted by hydroxyl or hydroxymethyl, or Ar is a phenyl optionally substituted by one or more CH_2NR^3-R^4 groups where R^3 is hydrogen or methyl and R^4 is CH_2CH_2OH, $CH_2(CH_3)CH_2OH$, $CH_2(phenyl)CH_2OH$, $CH_2CH_2(OH)phenyl$, $CH_2CH_2(OH)CH_2OH$, or Ar is a phenyl optionally substituted by one or more $CH_2OCH_2CH_2OCH_2OH$ groups, or Ar is a phenyl optionally substituted by one or more ethyl or hydroxymethyl groups.

16. (Previously presented) A compound according to claim 12 in which the Ar is phenyl substituted by C_1-C_8 alkyl and C_1-C_8 alkyl substituted by a hydroxy group.

17. (Original) A compound according to claim 12 which is:
4-(2-Ethyl-phenylamino)-2-(4-fluorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-3-hydroxymethyl-phenylamino)-2-(4-fluorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-{2-Ethyl-3-[(2-hydroxy-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-3-{[(2-hyroxy-ethyl)-methyl-amino]-methyl}-phenylamino)-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-{2-Ethyl-3-[(2-hydroxy-1-methyl-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-{2-Ethyl-3-[(*S*)-(2-hydroxy-1-phenyl-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-{2-Ethyl-3-[(2-hydroxy-2-phenyl-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-3-morpholin-4-ylmethyl-phenylamino)-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-[2-Ethyl-3-(3-hydroxy-pyrrolidin-1-ylmethyl)-phenylamino]-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-[2-Ethyl-3-((*R*)-2-hydroxymethyl-pyrrolidin-1-ylmethyl)-phenylamino]-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-{3-[(2,3-Dihydroxy-propylamino)-methyl]-2-ethyl-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-3-imidazol-1-ylmethyl-phenylamino)-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-[3-(2-Ethoxy-ethoxymethyl)-2-ethyl-phenylamino]-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

2-(4-Bromo-phenyl)-4-(2-ethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-phenylamino)-2-phenyl-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-3-hydroxymethyl-phenylamino)-2-phenyl-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

2-(4-Chloro-phenyl)-4-(2-ethyl-3-hydroxymethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

2-(4-Chloro-phenyl)-4-(2-ethyl-3-imidazol-1-ylmethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide
or a pharmaceutically acceptable salt thereof.

18. (Cancelled)

19. (Previously presented) A pharmaceutical composition comprising a compound of formula (I) as defined in claim 12 or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.

20. (Previously presented) A method of treating asthma mediated by JAK3 which comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I) as defined in claims 12 or a pharmaceutically acceptable salt thereof.

21. (Cancelled)

22. (Cancelled)

23. (Previously presented) A compound according to claim 12 in which R^1 is hydrogen or phenyl optionally substituted by fluoro or bromo.

24. (Previously presented) A compound according to claim 12 in which the Ar is phenyl substituted by C_1-C_8 alkyl and hydroxymethyl.